Dissolvable heart patch could spare patients from surgery

NCT ID NCT07529028

Not yet recruiting Disease control Sponsor: Lifetech Scientific (Shenzhen) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a new device called Absnow II that closes a common heart hole (atrial septal defect) and then dissolves over time. About 236 people with a hole between 5 and 26 mm will get either the new device or a standard one. The goal is to see if the new device works just as well and is safe, potentially avoiding the need for lifelong implants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Absnow II absorbable atrial septal defect occluder (a device that closes a hole in the heart and then dissolves over time)
What this could lead to: If successful, this could offer a safer, less invasive way to close certain heart holes, with the device dissolving after the hole heals, potentially reducing long-term risks.
What could go wrong: This is an early-stage trial with only 236 participants, so results may not apply to everyone. The device might not close the hole as effectively or could cause complications like blood clots or device movement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL SEPTAL DEFECT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial septal defect atrial septal defect, ostium secundum type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL SEPTAL DEFECT

More trials for these conditions

Other studies related to the condition(s) this trial covers.